Treatment of hypertension in chronic kidney disease

Seminars in Nephrology

Volumn 25, Issue 6, 2005, Pages 435-439

  Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Hypertension; Proteinuria

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; GUANFACINE; HYDRALAZINE; LOOP DIURETIC AGENT; METOPROLOL; MINERALOCORTICOID ANTAGONIST; MINOXIDIL; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MEAN ARTERIAL PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 27844454420     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2005.05.016     Document Type: Article

References (35)

1. P.J. Conion, J.J. Walshe, S.K. Heinle Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients J Am Soc Nephrol 7 1996 2658 2663
2. S. Gianconi, C. Levanti, E. Fommei Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension Am J Hypertension 2 1989 259 261
3. G. Mancia, G. Parati Ambulatory blood pressure monitoring and organ damage Hypertension 36 2000 894 900
4. A.J. Peixoto, D.A. Sica Ambulatory blood pressure monitoring in end-stage renal disease Blood Press Monit 2 1997 275 282
5. J.T. Wright Jr, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease Results from the AASK trial JAMA 288 2002 2421 2431
6. S. Klahr, A.S. Levey, G.J. Beck Modification of Diet in Renal Disease Study Group The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 330 1994 877 884
7. Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 BMJ 317 1998 703 713
8. R.O. Estacio, R.W. Schrier Antihypertensive therapy in type 2 diabetes Implications of the appropriate blood pressure control in diabetes (ABCD) trial Am J Cardiol 82 1998 9R 14R
9. R.W. Schrier, R.O. Estacio, A. Esler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 2002 1086 1097
10. R.D. Toto, H.C. Mitchell, R.D. Smith "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis Kidney Int 48 1995 851 859
11. J.T. Wright Jr, J.W. Kusek, R.D. Toto Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) pilot study Control Clin Trials 17 1996 3S 16S
12. J.T. Wright Jr, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease Results from the AASK trial JAMA 288 2002 2421 2431
13. P. Muntner, J. Coresh, J.C. Smith Plasma lipids and risk of developing renal dysfunction The atherosclerosis risk in communities study Kidney Int 58 2000 293 301
14. AASK Pilot Study Investigators A. Fogo, J.A. Breyer, M.C. Smith Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans A report from the African American Study of Kidney Disease (AASK) Trial Kidney Int 51 1997 244 252
15. M. Regalado, S. Yang, D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
16. E. Ritz, H. Ogata, S.R. Orth Smoking A factor promoting onset and progression of diabetic nephropathy Diabet Med 26 2000 54 63
17. M. Regalado, S. Yang, D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
18. N.B. Shulman, C.E. Ford, W.D. Hall The Hypertension Detection and Follow-up Program Cooperative Group Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program Hypertension 13 1989 I80 I93
19. H.M. Perry Jr, J.P. Miller, J.R. Fornoff Early predictors of 15-year end-stage renal disease in hypertensive patients Hypertension 25 1995 587 594
20. J.F. Mann, H.C. Gerstein, J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril The HOPE randomized trial Ann Intern Med 134 2001 629 636
21. P. Muntner, L.L. Hamm, J.W. Kusek The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 140 2004 9 17
22. C. Gouva, P. Nikolopoulos, J.P. Ioannidis Treating anemia early in renal failure patients slows the decline of renal function A randomized controlled trial Kidney Int 66 2004 753 760
23. National Kidney Foundation: KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:9-10, 1004
24. The Collaborative Study Group E.J. Lewis, L.G. Hunsicker, R.P. Bain The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
25. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
26. The Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group G. Maschio, D. Alberti, G. Janin Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med 334 1996 939 945
27. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Gissen Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
28. T.H. Jafar, P.C. Stark, C.H. Schmid Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis Ann Intern Med 139 2003 244 252
29. T.H. Jafar, C.H. Schmid, M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
30. T.H. Jafar, P.C. Stark, C.H. Schmid Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease Kidney Int 60 2001 1131 1140
31. M. Sarnak, T. Greene, X. Wang, G. Beck, J. Kusek, A. Collins, A. Levey The effect of a lower target blood pressure on the progression of kidney disease long-term follow-up of the modification of diet in renal disease study Ann Intern Med 142 5 2005 342 351 Mar 1
32. DASH-Sodium Collaborative Research Group F.M. Sacks, L.P. Svetkey, W.M. Vollmer Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet N Engl J Med 344 2001 3 10
33. P. Ruggenenti, A. Perna, R. Benini Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) J Am Soc Nephrol 9 1998 2096 2101
34. G.L. Bakris, M.R. Weir, S. Shanifar Effects of blood pressure level on progression of diabetic nephropathy Results from the RENAAL study Arch Intern Med 163 2003 1555 1565
35. M. Epstein, V. Buckalew, J. Altamirano Eplerenone reduces proteinuria in type II diabetes mellitus Implications for aldosterone involvement in the pathogenesis for renal dysfunction J Am Coll Cardiol 39 2002 249A